Stevanato Group expects a temporary headwind in 2027 as one of its two GLP-1 originator clients faces lower syringe demand, so it set a safe floor of low single-digit growth. The company is backfilling excess capacity with other biologic customers and expects margin expansion and a step up in free cash flow in fiscal 2027. Detailed guidance will come in March.
STVN · Stevanato Group S.p.A.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 60%
- Last earnings
- Nov 3, 2026
- Price history
- Jul 2021 to Nov 2026
Up next
Latest documents
Stevanato Group S.p.A. reported third-quarter 2026 revenue growth of 8% to €326.1 million, while adjusted EBITDA margin rose 150 basis points to 27.2%. Full-year guidance was reiterated, but lower GLP1 volumes are expected to temporarily moderate 2027 growth to low single digits.
Stevanato Group S.p.A. reported revenue of 901,640 thousand euros for the nine months ended September 30, 2026, versus 839,800 thousand euros, while net profit was 92,821 thousand euros versus 92,279 thousand euros.
Stevanato Group reported Q3 2026 revenue growth of 8%, driven by BDS organic growth of 11%, while adjusted EBITDA rose 14% to €88.8M and margin expanded to 27.2%. It expects lower GLP-1 volumes than previously anticipated for FY27.
Stevanato Group reported third-quarter 2026 revenue of €326.1 million, up 8%, and adjusted EBITDA of €88.8 million. The company maintained fiscal 2026 guidance of €1.260 billion to €1.280 billion in revenue.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STVN
this stock
Stevanato Group S.p.A.
|
$4.27B | -22.2% | — | — | 0.3% |
|
ISRG
Intuitive Surgical Inc
|
$138.33B | -29.5% | +20.5% | 48.4 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$57.96B | — | +8.2% | 94.2 | 3.0% |
|
MDLN
Medline Inc.
|
$48.72B | -11.8% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$35.70B | -5.7% | +10.5% | — | 3.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 25
Stevanato Group expects a temporary headwind in 2027 as one of its two GLP-1 originator clients faces lower syringe demand, so it set a safe floor of low single-digit growth. The company is backfilling excess capacity with other biologic customers and expects margin expansion and a step up in free cash flow in fiscal 2027. Detailed guidance will come in March.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STVN | -1.0% | -19.7% | -16.7% | -19.3% | -22.2% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +7.6% | -10.5% | -7.5% | -10.5% | -23.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.